Kalvista Pharmaceuticals Inc (NASDAQ:KALV) has been assigned a consensus recommendation of “Buy” from the nine brokerages that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $27.33.

KALV has been the topic of a number of recent research reports. Cantor Fitzgerald began coverage on Kalvista Pharmaceuticals in a research report on Friday, September 21st. They set an “overweight” rating and a $32.00 price target on the stock. Stifel Nicolaus began coverage on Kalvista Pharmaceuticals in a research report on Monday, October 15th. They set a “buy” rating on the stock. BidaskClub downgraded Kalvista Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 9th. Zacks Investment Research downgraded Kalvista Pharmaceuticals from a “buy” rating to a “sell” rating in a research report on Thursday, September 20th. Finally, Jefferies Financial Group began coverage on Kalvista Pharmaceuticals in a research report on Tuesday, October 30th. They set a “buy” rating and a $30.00 price objective on the stock.

KALV opened at $22.40 on Wednesday. Kalvista Pharmaceuticals has a 12-month low of $7.73 and a 12-month high of $25.57. The firm has a market cap of $393.57 million, a PE ratio of -14.64 and a beta of 2.94.

Kalvista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings results on Friday, September 14th. The specialty pharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.14). Kalvista Pharmaceuticals had a negative return on equity of 56.24% and a negative net margin of 132.38%. The firm had revenue of $3.72 million for the quarter, compared to the consensus estimate of $4.11 million. On average, research analysts forecast that Kalvista Pharmaceuticals will post -2.07 earnings per share for the current fiscal year.

In related news, Director Albert Cha acquired 1,058,824 shares of the company’s stock in a transaction that occurred on Monday, September 10th. The shares were bought at an average price of $17.00 per share, with a total value of $18,000,008.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 49.10% of the stock is owned by company insiders.

Hedge funds have recently modified their holdings of the stock. Stanley Laman Group Ltd. boosted its position in Kalvista Pharmaceuticals by 48.3% during the second quarter. Stanley Laman Group Ltd. now owns 67,082 shares of the specialty pharmaceutical company’s stock valued at $545,000 after purchasing an additional 21,861 shares in the last quarter. Spark Investment Management LLC acquired a new stake in Kalvista Pharmaceuticals in the second quarter worth about $108,000. DRW Securities LLC boosted its holdings in Kalvista Pharmaceuticals by 37.3% in the second quarter. DRW Securities LLC now owns 20,600 shares of the specialty pharmaceutical company’s stock worth $167,000 after acquiring an additional 5,600 shares in the last quarter. Stonepine Capital Management LLC acquired a new stake in Kalvista Pharmaceuticals in the third quarter worth about $3,053,000. Finally, Interwest Venture Management Co. boosted its holdings in Kalvista Pharmaceuticals by 17.8% in the third quarter. Interwest Venture Management Co. now owns 388,766 shares of the specialty pharmaceutical company’s stock worth $8,596,000 after acquiring an additional 58,824 shares in the last quarter. 73.16% of the stock is currently owned by institutional investors.

Kalvista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Recommended Story: What are the reasons investors use put options?

Analyst Recommendations for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.